At the pre-specified interim analysis (IA; median follow-up, 17.4 months), IMbrave050 met its primary endpoint of improved independent review facility (IRF)–assessed recurrence-free survival (RFS) in patients with high-risk hepatocellular carcinoma (HCC). The RFS hazard ratio (HR) for atezolizumab plus bevacizumab vs.
active surveillance was 0.72 (adjusted 95% CI 0.53–0.98; p = 0.012), and overall survival (OS) data were immature. Here, we report an updated post hoc analysis of RFS and the second IA of OS, along with additional data.
Journal of Hepatology published a clinical update in Research Highlights on 22 Jan 2026.
The item focuses on Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
Review the original article for the full source wording and details.